309 results about "Nephrotic syndrome" patented technology

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Devices, systems and methods using feedback from sensors for the treatment of pathological conditions such as Kidney Disease (KD) alone, Heart Failure (HF) alone, KD with concomitant HF or cardiorenal diseases syndrome (CRS) are described. The devices, systems and methods monitor and gather patient information and administer one or more diuretic or natriuretic molecules.

The invention discloses a new traditional Chinese medicine composition for treating nephrotic syndrome and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs such as American ginseng, ginseng, codonopsis pilosula, unprocessed astragalus mongholicus, Chinese yam, turtle shell, tortoise plastron, cornu cervi degelatinatum, fruit of Chinese wolfberry, root of Chinese trichosanthes, fruit of Chinese magnoliavine, seed of Chinese dodder, herba cistanche, Chinese caterpillar fungus, prepared rehmannia root, polygonum multiflorum, fructus ligustri lucidi, dried orange peel, myristica fragrans, fructus amomi, semen euryales, mangnolia officinalis, fructus chebulae, fructus rosae laevigatae, fructus alpiniae oxyphyllae, oyster, drynaria rhizome, dogwood, root-bark of Chinese wolfberry, phellodendron, fructus gardenia, white atractylodes rhizome, lucid asparagus, ophiopogon japonicus, herba epimedii, rhizoma anemarrhenae, root of kudzu vine and the like. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of proteinuria, hypoalbuminemia, hematuresis, generaldropsy, listlessness, poor physical strength, inappetence, insomnia and amnesia, hypomnesis and the like of the patients suffering from the nephrotic syndrome and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible medicines specified in National Formulary, the invention has the advantages of low cost, basically no toxic and side effects and the like.

The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

The invention discloses a composite kidney-benefiting medicine and belongs to Chinese herbal composite medicine. The composite kidney-benefiting medicine comprises astragalus, angelica sinensis, red peony root, rhizoma chuanxiong, glossy privet fruit, eclipta, lalang grass rhizome, moutan bark, fructus kochiae and glycyrrhiza. The composite kidney-benefiting medicine can effectively cure pure simple hematuresis and hematuresis proteinuria, comprises immune globulin A (IgA) nephropathy, anaphylatic purpura nephritis, nephrotic syndrome, comprises nephritis type with hematuresis, can confront side effect of nephrotic syndrome which is cured by hormone, can play roles in promoting blood circulation to remove blood stasis and preventing and curing hypercoagulable state and has the advantages of being prominent in curative effect, convenient to take and good in taste.

The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The invention provides a kit for detecting a serum anti-Annexin A2-IgG antibody. The detection kit of the invention adopts a target antigen Annexin A2 corresponding to an anti-Annexin A2-IgG antibodyof a primary nephrotic syndrome-related biomarker, uses human anti-tag peptide IgG as a standard substance for quantitative detection, and utilizes a biotin-labeled detection antibody and an enzyme-labeled streptavidin amplification system, thereby improving the accuracy and sensitivity of serum anti-Annexin A2-IgG antibody detection, and providing a better detection method for the diagnosis and treatment of primary nephrotic syndrome with the anti-Annexin A2-IgG antibody.

The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I

wherein R¹, R² and R³ are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I

The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention relates to a medicine for curing kidney diseases. Said medicine is a Chinese medicine capsule preparation made from 20 Chinese medicinal materials of cooked rehmannia root, silkworm, bupleurum root, Chinese yam, astragalus root, leech and others through the processes of conventional water and alcohol double extraction. Said medicine can be used for curing the diseases of acute and chronic nephritis, purpuric nephritis, hepatitis B related nephritis, lupoid nephritis, nephrotic syndrome, renal insufficiency and diabetic nephritis, etc. Its cure rate is up to 92%.

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

The Chinese medicine for curing chronic nephritis and nephrotic syndrome, specially for curing side effect resulted from application of hormone and rebound phenomenon produced after hormone extenuation and medicine withdrawal with good therapeutic effect is a water-paste pill made up by using 8 Chinese medicinal matterials of lonicera stem and leaf, astragalus root, flowery knotweed, dioscorea root, pseudotellaria root, licorice, placenta powder and rhubarb as raw material. Its therapeutic effect is reliable, and its effective rate is above 95%, and it has no toxic side effect.

The present invention relates to a Chinese medicine composition for curing nephritic syndrome. Said Chinese medicine composition includes 5 Chinese medicinal materials of black soybean, astragalus root, atractylodes root, Chinese yam and Chinese angelica root. Said Chinese medicine composition can be made into tablet, capsule and granules preparation.

The invention discloses a traditional Chinese medicine for treating nephrotic syndrome, which is characterized by comprising the following components: 5-15g of glossy privet fruit, 10-20g of azuki bean, 6-12g of cordate houttuynia, 10-20g of plantain herb, 5-15g of root of hairy asiabell, 6-12g of Phellodendron amurense, 5-15g of Astragalus membranaceus, 5-15g of Chinese caterpillar fungus, and so on. The traditional Chinese medicine for treating nephrotic syndrome is prepared by a simple process, is convenient to take, and has remarkable treatment effect on nephrotic syndrome.

The invention discloses a compound oral Chinese patent medicament for treating gout, which consists of the following raw materials in percentage by weight based on crude medicaments: 5 to 20 percent of phellodendron, 5 to 20 percent of root of common peony, 5 to 30 percent of sevenlobed yam rhizome, 5 to 30 percent of desmodium, 3 to 10 percent of mastic, 3 to 10 percent of myrrh, 5 to 25 percent of suberect spatholobus stem, 5 to 20 percent of rhizoma atractylodis, 5 to 28 percent of oriental waterplantain rhizome, 5 to 20 percent of medicinal cyathula root, and 5 to 20 percent of root of largeleaf gentian. The invention discloses a preparation method for the medicament, and the formulations of the medicament are tablets, capsules, granules, oral liquid, dropping pills, and other common formulations. The compound oral Chinese patent medicament is used for treating acute and chronic gout, gouty arthritis, gouty stone, and gouty nephrotic syndrome, is a new medicament with obvious curative effects and safe administration for clinical treatment, and has significant application value.

The present invention relates to method of treating a patient with a condition involving increased vascular permeability or increased angiogenesis comprising administering to the patient a therapeutically effective amount of PEDF, PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide, a homolog of the PEDF 44 AA peptide wherein amino acid residues glutamate the (101) amino acid position, isoleucine at the (103) amino acid position, leucine at the (112) and serine at the (115) amino acid position are unchanged, or an agent that activates the PEDF receptor. Conditions for treatment include, but are not limited to, sepsis acute respiratory distress syndrome, nephrotic syndrome, diabetic neuropathy, preproliferative diabetic retinopathy, cancer or proliferative diabetic retinopathy.

The invention belongs to the technical field of model establishment and evaluation methods with an aim to solve problems about low flexibility and poor accuracy in an existing model establishment andevaluation method for the nephritic syndrome rats and provides a model establishment and evaluation method for the nephritic syndrome rats. Changes of endogenous metabolites in the urine of terminal products are analyzed by metabolomics, all 1 HNMR spectra are processed through MestReNova software to acquire integral data, statistical analysis of the content of 12 biomarkers is combined with, thechanges of the mean value of the 12 biomarkers in the urine before and after modeling reflect the change trend of the urine metabolite content in the nephritic syndrome rats, and models of nephritic syndrome are evaluated in a targeted manner. Dynamic body contours before and after modeling is reflected comprehensively, flexibly and systematically, rationality and scientific nature of model reproduction are comprehensively reflected, the reliable evaluation method for new drug development and pharmacological research is provided, and the method is efficient, rapid, noninvasive and high in specificity.

The invention relates to medical technology field, discloses a glucocorticoid synergist, and is characterized in adopting total ginsenoside as synergist. Its proportions are respectively as following: total ginsenoside 200mg-1200mg and dexamethasone 0.75-187.5mg; total ginsenoside 200mg-1200mg and betamethason 0.75-187.5mg; total ginsenoside 200-1200mg, and prednisone 5-1250mg, total ginsenoside 200-1200mg, and precortisyl 5-1250mg; total ginsenoside 200mg-1200mg, and urbason 4-1000mg; total ginsenoside 200-1200mg, and cortisone 25-6250mg; and total ginsenoside 200-1200mg, and hydrocortisone 20-5000mg.Total ginsenoside as glucocorticoid synergist can be used in the treatment of diseases requiring long term or a large amount of glucocorticoid such as systemic lupus erythematosus, nephrotic syndrome, polymyositis, and rheumatoid arthritis.

The invention relates to a Chinese medicinal combination for treating nephrotic syndrome which is prepared from more than ten kinds of Chinese medicinal herbs including white atractylodes rhizome, raw astragalus root, red phaseolus bean and corn stigma.